• 1. Characteristics of ignition delay of hypergolic ionic liquids combined with 1-amino-4-methylpiperazine
  Kyung Su Shin,Hoi-Gu Jang,Soon Hee Park,Sung June Cho RSC Adv. 2023 13 18960
• 2. Design, synthesis and characterization of novel dioxime ligand-based cobaloxime compounds for application in the coupling of CO2 with epoxides
  Ahmet Kilic,Seyithan Akdag,Emine Aytar,Mustafa Durgun,Mahmut Ulusoy New J. Chem. 2016 40 7901
• 3. Novel fluorescent sensors based on benzimidazo[2,1-a]benz[de]isoquinoline-7-one-12-carboxylic acid for Cu2+
  Zheng Liu,Yuhua Qi,Chaoxia Guo,Yingying Zhao,Xiaofeng Yang,Meishan Pei,Guangyou Zhang RSC Adv. 2014 4 56863
• 4. Novel fluorescent sensors based on benzimidazo[2,1-a]benz[de]isoquinoline-7-one-12-carboxylic acid for Cu2+
  Zheng Liu,Yuhua Qi,Chaoxia Guo,Yingying Zhao,Xiaofeng Yang,Meishan Pei,Guangyou Zhang RSC Adv. 2014 4 56863
• 5. Preparation and characterization of diarylphosphazene and diarylphosphinohydrazide complexes of titanium, tungsten and ruthenium and phosphorylketimido complexes of rhenium
  Andrew R. Cowley,Jonathan R. Dilworth,Alison K. Nairn,Alasdair J. Robbie Dalton Trans. 2005 680

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-alkylpiperazines

Professional Introduction to 4-Methylpiperazin-1-amine (CAS No. 6928-85-4)

4-Methylpiperazin-1-amine, identified by its Chemical Abstracts Service number (CAS No. 6928-85-4), is a significant compound in the field of pharmaceutical chemistry and drug development. This heterocyclic amine derivative has garnered considerable attention due to its versatile applications and structural properties that make it a valuable intermediate in synthesizing various bioactive molecules.

The molecular structure of 4-methylpiperazin-1-amine consists of a piperazine ring substituted with a methyl group at the 4-position and an amine group at the 1-position. This configuration imparts unique chemical reactivity and pharmacological potential, making it a preferred building block in medicinal chemistry. The compound's ability to act as a pharmacophore in drug design has been exploited in the development of several therapeutic agents targeting neurological and cardiovascular disorders.

Recent advancements in pharmaceutical research have highlighted the role of 4-methylpiperazin-1-amine in the synthesis of novel drugs. Its incorporation into molecular frameworks has led to the discovery of compounds with enhanced binding affinity and improved pharmacokinetic profiles. For instance, studies have demonstrated its utility in developing selective serotonin reuptake inhibitors (SSRIs) and vasodilators, where the piperazine moiety contributes to the compound's ability to interact with biological targets effectively.

The chemical reactivity of 4-methylpiperazin-1-amine allows for diverse functionalization strategies, enabling chemists to tailor its properties for specific applications. It can undergo nucleophilic substitution reactions, forming amides, ureas, and other derivatives that are crucial in drug synthesis. Additionally, its solubility characteristics make it suitable for formulation in various pharmaceutical delivery systems, enhancing drug bioavailability and efficacy.

In the context of contemporary drug discovery, 4-methylpiperazin-1-amine has been integrated into high-throughput screening (HTS) protocols to identify new lead compounds. Its structural motifs are frequently employed in virtual screening campaigns due to their known interaction patterns with biological receptors. This has accelerated the identification of potential therapeutic candidates, particularly in the treatment of central nervous system (CNS) disorders.

The synthesis of 4-methylpiperazin-1-amine typically involves multi-step organic reactions, starting from readily available precursors such as piperazine and formaldehyde derivatives. Catalytic hydrogenation or reductive amination methods are commonly employed to introduce the methyl group at the 4-position while preserving the amine functionality. These synthetic routes have been optimized for scalability and cost-effectiveness, ensuring that the compound remains accessible for industrial applications.

Evaluation of 4-methylpiperazin-1-amine's pharmacological properties has revealed its potential as an adjuvant in combination therapies. Researchers have observed synergistic effects when it is co-administered with other drugs, particularly in managing chronic conditions such as hypertension and depression. The compound's ability to modulate neurotransmitter pathways without significant side effects makes it an attractive candidate for further clinical investigation.

The safety profile of 4-methylpiperazin-1-amine has been thoroughly assessed through preclinical studies, which have provided insights into its metabolic pathways and potential toxicity endpoints. These findings have informed dosing regimens and formulation strategies aimed at minimizing adverse effects while maximizing therapeutic benefits. Regulatory agencies have reviewed this data extensively, ensuring that the compound meets stringent safety standards for human use.

The future prospects for 4-methylpiperazin-1-amine in pharmaceutical development appear promising, with ongoing research exploring its role in emerging therapeutic areas. Innovations in synthetic methodologies continue to enhance its accessibility, while advances in computational chemistry are facilitating more efficient drug design processes incorporating this scaffold. Collaborative efforts between academia and industry are expected to yield novel applications that leverage its unique chemical and pharmacological attributes.

• 41465-90-1(1-Piperazineethanamine,4-amino-N,N-dimethyl-)
• 34924-93-1(1-Piperazinamine,4-ethyl-)
• 56964-23-9(1-Piperazinamine, 4-(2-propynyl)-)
• 924-29-8(Ethanamine, N,N-diethyl-2-hydrazino-)
• 471925-16-3(4-(2-Aminoethyl)piperazin-1-amine)
• 30651-60-6(1-Piperazinamine)
• 40675-60-3(4-methylpiperazinoamine dihydrochloride monohydrate)
• 106-59-2(1,4-Piperazinediamine)
• 13562-46-4(1-(2-hydrazinylethyl)-4-methylpiperazine)
• 52722-82-4(1-Piperazinamine, N,N,4-trimethyl-)